Ferring Pharmaceuticals Inc

General

Total Cases21
Active Cases3
Patents2
TypeOperating Company
Elite Ratings
--
--
--
--

Ratings

Experience
Grade
Trend
DCT
L3
B
PTAB
--
--
--
CAFC
L3
E

Analytics

Cases

Litigated Patents

Ratings Trends

Recent Dockets

Entered
Case
Description
09/13/24
RESPONSE to Motion re [495] MOTION for Leave to File Reply in Support of Motion for Reconsideration [Opposition] filed by Finch Therapeutics Group, Inc., Finch Therapeutics Holdings, LLC., Finch Therapeutics, Inc., Regents of the University of Minnesota. (Farnan, Kelly) (Entered: 09/13/2024)
09/13/24
Set Post Trial Briefing Schedule re [496] Motion Post-Trial Motion for Enhanced Damages, Ongoing Royalty, and Pre- and Post-Judgment Interest Pursuant to Order on D.I. 490 and [497] Renewed Motion for Judgment as a Matter of Law: Opening Briefs due 9/26/2024. Responsive Briefs due 10/30/2024. Reply Briefs due 11/21/2024. (*Briefing Schedule set by D.I. [490] ) (ceg) (Entered: 09/13/2024)
09/12/24
MOTION for Judgment as a Matter of Law Ferring/Rebiotix's Renewed Motion for Judgment as a Matter of Law - filed by Ferring Pharmaceuticals Inc., Rebiotix Inc.. (Attachments: # [1] Text of Proposed Order)(Bourke, Mary) (Entered: 09/12/2024)
09/12/24
Renewed MOTION for Judgment as a Matter of Law - filed by Ferring Pharmaceuticals Inc., Rebiotix Inc. (Attachments: # [1] Text of Proposed Order)(Bourke, Mary) Modified on 9/13/2024 (ceg). (Entered: 09/12/2024)
09/12/24
MOTION Post-Trial Motion for Enhanced Damages, Ongoing Royalty, and Pre- and Post-Judgment Interest Pursuant to Order On D.I.490 re [490] , SO ORDERED,, Set Deadlines, - filed by Finch Therapeutics Group, Inc., Finch Therapeutics Holdings, LLC., Regents of the University of Minnesota. (Attachments: # [1] 7.1.1 Certification, # [2] Text of Proposed Order)(Farnan, Kelly) (Entered: 09/12/2024)
09/12/24
Post-Trial MOTION for Enhanced Damages, Ongoing Royalty, and Pre- and Post-Judgment Interest Pursuant to Order on D.I.490 - filed by Finch Therapeutics Group, Inc., Finch Therapeutics Holdings, LLC., Regents of the University of Minnesota. (Attachments: # [1] 7.1.1 Certification, # [2] Text of Proposed Order) (Farnan, Kelly) Modified on 9/13/2024 (ceg). (Entered: 09/12/2024)
08/30/24
MOTION for Leave to File Reply in Support of Motion for Reconsideration - filed by Ferring Pharmaceuticals Inc., Rebiotix Inc.. (Attachments: # [1] Exhibit Reply in Support of Motion for Reconsideration Regarding Summary Judgment of Patent Ineligibility Under 35 U.S.C. § 101, # [2] Text of Proposed Order)(Bourke, Mary) (Entered: 08/30/2024)
08/28/24
ORAL ORDER: The parties' Notices of Lodging, (D.I. 487 , 489 ) are stricken. Demonstrative exhibits are not evidence. Should a party contend that a demonstrative exhibit was inappropriately permitted to be shown to the jury over its objection, it shall refile the particular demonstrative exhibit(s) along with a cover letter pointing to the portion of the record where such objection was made. Ordered by Judge Jennifer L. Hall on 8/28/2024. (ceg) (Entered: 08/28/2024)
08/28/24
Remark: The Notices of Lodging Trial Demonstratives previously filed at D.I. 487 and 489 have been removed per the Oral Order at D.I. 494. (ceg) (Entered: 08/28/2024)
08/27/24
ANSWERING BRIEF in Opposition re [485] MOTION for Reconsideration re [421] Order Ferring/Rebiotix's Motion for Reconsideration Regarding Summary Judgment of Patent Ineligibility Under 35 U.S.C. § 101 filed by Finch Therapeutics Group, Inc., Finch Therapeutics Holdings, LLC., Finch Therapeutics, Inc., Regents of the University of Minnesota.Reply Brief due date per Local Rules is 9/3/2024. (Farnan, Kelly) (Entered: 08/27/2024)